TY - JOUR
T1 - Comparing the clinical impact of pancreatic cyst surveillance programs
T2 - A trial of the ECOG-ACRIN cancer research group (EA2185)
AU - EA2185 Team
AU - Weinberg, David S.
AU - Gatsonis, Constantine
AU - Zeh, Herbert J.
AU - Carlos, Ruth C.
AU - O'Dwyer, Peter J.
N1 - Copyright © 2020 Elsevier Inc. All rights reserved.
PY - 2020/10
Y1 - 2020/10
N2 - Background: The optimal surveillance strategy for pancreatic cysts, which occur in up to 20% of the adult population, is ill defined. The risk of malignant degeneration of these cysts is low, however the morbidity and mortality associated with pancreatic cancer are high. Two clinical surveillance guidelines are in regular use. Both the Fukuoka and American Gastroenterological Association (AGA) guidelines rely on radiographic and endoscopic imaging. They differ primarily in their recommended frequencies of interval surveillance imaging. While evidence driven clinical guidelines should promote higher quality care, competing guidelines on the same topic may provide discordant recommendations and potential reduction in the quality and/or value of care. Objectives: The primary objective is to compare the clinical effectiveness of the two surveillance guidelines to identify patients most likely to benefit from pancreatic resection. Secondary objectives include comparison of resource utilization, patient reported outcomes, incidental findings are other clinical outcomes. Methods: 4606 asymptomatic patients with newly identified pancreatic cysts ≥1 cm in diameter will be randomized 1:1 to high intensity (Fukuoka) or low intensity (AGA) surveillance. All participants will be followed prospectively for 5 years. Conclusion: Differing guidelines confuse providers, patients and policymakers. This large, prospective, randomized trial will compare the clinical effectiveness and resource allocation requirements of two guidelines addressing a common clinical entity. ClinicalTrials.gov identifier: NCT04239573.
AB - Background: The optimal surveillance strategy for pancreatic cysts, which occur in up to 20% of the adult population, is ill defined. The risk of malignant degeneration of these cysts is low, however the morbidity and mortality associated with pancreatic cancer are high. Two clinical surveillance guidelines are in regular use. Both the Fukuoka and American Gastroenterological Association (AGA) guidelines rely on radiographic and endoscopic imaging. They differ primarily in their recommended frequencies of interval surveillance imaging. While evidence driven clinical guidelines should promote higher quality care, competing guidelines on the same topic may provide discordant recommendations and potential reduction in the quality and/or value of care. Objectives: The primary objective is to compare the clinical effectiveness of the two surveillance guidelines to identify patients most likely to benefit from pancreatic resection. Secondary objectives include comparison of resource utilization, patient reported outcomes, incidental findings are other clinical outcomes. Methods: 4606 asymptomatic patients with newly identified pancreatic cysts ≥1 cm in diameter will be randomized 1:1 to high intensity (Fukuoka) or low intensity (AGA) surveillance. All participants will be followed prospectively for 5 years. Conclusion: Differing guidelines confuse providers, patients and policymakers. This large, prospective, randomized trial will compare the clinical effectiveness and resource allocation requirements of two guidelines addressing a common clinical entity. ClinicalTrials.gov identifier: NCT04239573.
KW - Adult
KW - Diagnostic Imaging
KW - Humans
KW - Pancreatic Cyst/diagnostic imaging
KW - Pancreatic Neoplasms/diagnosis
KW - Prospective Studies
KW - Treatment Outcome
KW - United States/epidemiology
UR - http://www.scopus.com/inward/record.url?scp=85091913698&partnerID=8YFLogxK
U2 - 10.1016/j.cct.2020.106144
DO - 10.1016/j.cct.2020.106144
M3 - Article
C2 - 32920242
AN - SCOPUS:85091913698
SN - 1551-7144
VL - 97
SP - 106144
JO - Contemporary Clinical Trials
JF - Contemporary Clinical Trials
M1 - 106144
ER -